Amerise Biosciences Limited (BOM:531681)

Amerise Biosciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Operating Revenue	-	-	-	90.08	-	-
Other Revenue	0.36	0.36	0.09	5.69	-1.69	0.01
Revenue	0.36	0.36	0.09	95.77	-1.69	0.01
Revenue Growth (YoY)	17800.00%	307.95%	-99.91%	-	-	-99.95%
Cost of Revenue	-	-	-	89.15	-	-
Gross Profit	0.36	0.36	0.09	6.63	-1.69	0.01
Selling, General & Admin	0.61	0.89	0.2	0.53	0.47	0.39
Other Operating Expenses	0.53	0.93	1.54	0.6	0.63	1.1
Operating Expenses	1.14	1.82	1.75	1.13	1.68	1.49
Operating Income	-0.78	-1.46	-1.66	5.5	-3.37	-1.48
Other Non Operating Income (Expenses)	-0	-0	-0	-0	-	-
EBT Excluding Unusual Items	-0.79	-1.46	-1.66	5.49	-3.37	-1.48
Pretax Income	-0.79	-1.46	-1.66	5.49	-3.37	-1.48
Income Tax Expense	-	-	-0.47	-	-	0.01
Net Income	-0.79	-1.46	-1.19	5.49	-3.37	-1.49
Net Income to Common	-0.79	-1.46	-1.19	5.49	-3.37	-1.49
Shares Outstanding (Basic)	-	66	66	66	66	66
Shares Outstanding (Diluted)	-	66	66	66	66	66
EPS (Basic)	-	-0.02	-0.02	0.08	-0.05	-0.02
EPS (Diluted)	-	-0.02	-0.02	0.08	-0.05	-0.02
Gross Margin	100.00%	100.00%	100.00%	6.92%	-	100.00%
Operating Margin	-218.99%	-405.85%	-1884.09%	5.74%	-	-25902.71%
Profit Margin	-219.83%	-406.96%	-1351.14%	5.73%	-	-26042.30%
EBIT	-0.78	-1.46	-1.66	5.5	-3.37	-1.48
EBIT Margin	-218.99%	-	-	5.74%	-	-
Revenue as Reported	0.36	0.36	0.09	95.77	-1.69	0.01
Advertising Expenses	-	-	-	-	-	0.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.